Big pharma claims Supreme victory

In a ruling heralded as a big win for big pharma -- and a loss for smaller biotechs -- the Supreme Court ruled that drug developers can experiment with compounds still under patent. Industry groups joined the AARP in trumpeting the 9-0 ruling, saying that it should reduce the cost of drug trials and speed new drugs. But experts noted that the ruling is likely to hurt small biotechs that need licensing funds on patented compounds to grow. Some also said that the ruling greatly expanded the scope of a 1984 law that was intended to speed the development of generic drugs.

- read this story from the Los Angeles Times for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.